Human iPSC-Derived Sensory Neurons: A Scalable Model for HSV-1 Latency and Reactivation

Study Background and Research Question

Herpes simplex virus 1 (HSV-1) is a widespread human pathogen responsible for recurrent mucocutaneous lesions, keratitis, and life-threatening encephalitis. Following initial lytic infection in epithelial cells, HSV-1 establishes lifelong latency in peripheral neurons, particularly sensory and autonomic ganglia. Reactivation from latency underlies recurrent disease and transmission. While animal models have illuminated many aspects of HSV-1 neurotropism and latency, significant differences between rodent and human neurons—regarding chromatin regulation, immune signaling, and viral gene silencing—limit the translational relevance of these systems. The absence of scalable, physiologically relevant human neuron models has hindered mechanistic studies and therapeutic development aimed specifically at the latent viral state (paper). The primary research question addressed by Oh et al. (2025) was whether human inducible pluripotent stem cells (hiPSCs) could be rapidly and reproducibly differentiated into sensory neurons that support HSV-1 latency and reactivation, thus providing a tractable in vitro system for dissecting latent infection mechanisms (paper).

Key Innovation from the Reference Study

The central innovation of this work is the development and validation of a robust, scalable protocol for differentiating hiPSCs into functionally mature sensory neurons. These neurons not only display the expected electrophysiological properties and ion channel expression profiles but also support all key features of HSV-1 latency observed in vivo:

• Suppression of lytic viral gene expression
• Absence of infectious virus production
• Efficient expression of latency-associated transcripts (LAT)
• Deposition of heterochromatic marks on the viral genome
• Responsiveness to canonical reactivation stimuli

This model overcomes previous limitations of non-human systems and non-neuronal cell lines, offering a powerful tool for mechanistic studies and preclinical testing (paper).

Methods and Experimental Design Insights

The authors adapted and optimized differentiation protocols to generate sensory neurons from hiPSCs within a condensed timeframe. The protocol included:

• Patterning hiPSCs with small molecule inhibitors and growth factors to induce neural crest/sensory neuron fate
• Validation of neuronal identity through electrophysiology, immunostaining, and transcriptomic profiling
• Infection of mature neurons with HSV-1 under conditions favoring latency establishment
• Assessment of viral gene expression (lytic vs. LAT), infectious virus production, and chromatin status
• Application of chemical reactivation stimuli (e.g., forskolin, PI3 kinase inhibitors) to induce viral reactivation

Notably, latency was defined by the absence of infectious virus and reduced lytic gene expression, with parallel upregulation of LAT and enrichment of heterochromatin markers (e.g., H3K9me3, H3K27me3) on the viral genome (paper).

Protocol Parameters

• assay | hiPSC sensory neuron differentiation | 14–21 days | enables rapid, scalable production of human neurons | proven to yield functionally mature neurons in vitro | paper
• assay | HSV-1 infection MOI | 0.1–1 | ensures efficient latent infection without overwhelming cytopathic effect | balances initial viral load and neuron survival | paper
• assay | LAT expression assessment | RT-qPCR, RNA-FISH | confirms successful latency establishment | LAT is the hallmark of latent HSV-1 | paper
• assay | Chromatin immunoprecipitation (ChIP) for H3K9me3/H3K27me3 | endpoint: days 7–14 post-infection | allows detection of heterochromatin formation on viral genome | recapitulates in vivo latency epigenetics | paper
• assay | Reactivation stimulus | forskolin (10 μM), PI3K inhibitor (LY294002, 20 μM) | triggers latent virus reactivation | mimics known stress signals in neurons | paper
• assay | TGF-β pathway inhibition (optional for mechanistic studies) | SB 431542, 10 μM | may be used to dissect TGF-β involvement in neuronal differentiation or viral reactivation | workflow_recommendation

Core Findings and Why They Matter

The newly established hiPSC-derived sensory neuron system recapitulates the key molecular and epigenetic signatures of HSV-1 latency seen in human ganglia. Latently infected neurons display suppressed lytic transcript levels, absence of infectious virus, strong LAT expression, and persistent heterochromatin on the viral genome. Importantly, the latent state can be disrupted by physiologically relevant stimuli, leading to robust viral reactivation. This demonstrates the utility of the model for both mechanistic studies and screening of latency-reversing or latency-promoting interventions (paper). The impact of this work is significant: it provides a scalable, genetically tractable human neuron model for HSV-1 latency, enabling exploration of neuron-intrinsic and extrinsic factors regulating viral persistence. The system can facilitate the discovery of therapeutic strategies targeting latent reservoirs—an urgent unmet need, as current antivirals do not clear latent virus (paper).

Comparison with Existing Internal Articles

While the reference paper does not directly investigate the TGF-β pathway or ALK5 inhibition, there is a methodological parallel in the use of small molecule inhibitors to modulate differentiation and signaling pathways during neuronal specification. Internal resources such as the "SB 431542: Next-Gen Insights for TGF-β Pathway and Stem Cell Research" article provide detailed protocols for using ALK5 inhibitors, like SB 431542, to enhance the efficiency and purity of hiPSC-derived lineages. In particular, SB 431542 is frequently employed to block TGF-β/ALK5 signaling during early neural induction, supporting robust neuronal differentiation and reducing unwanted mesendodermal fates (internal: workflow_recommendation). Additionally, "SB 431542: ALK5 Inhibitor Empowering Advanced TGF-β Pathway Research" discusses its use in cellular assays for understanding immunological and proliferative cues, which may be relevant for dissecting neuron-immune interactions during viral latency or reactivation. Thus, while the reference study's focus is virological modeling, the techniques and reagents highlighted in internal resources are directly applicable for optimizing neural differentiation protocols and studying pathway-specific effects in similar systems.

Limitations and Transferability

Despite its innovation, the model has several limitations:

• It remains an in vitro system and may not fully recapitulate the complex microenvironment of human ganglia, including immune cell interactions and vascularization.
• Genetic and epigenetic heterogeneity among hiPSC lines could influence differentiation outcomes and HSV-1 latency characteristics.
• Long-term culture stability and the fidelity of reactivation stimuli to in vivo stressors require further validation.
• The current model does not address the contribution of non-neuronal cell types (e.g., glia) present in native ganglia.

Nevertheless, the platform represents a substantial advance over previous models and is readily adaptable for mechanistic studies, genetic manipulation, and drug screening (paper).

Why this cross-domain matters, maturity, and limitations

The intersection of antiviral research and stem cell biology is crucial for understanding persistent viral infections in a human context. The ability to modulate signaling pathways, such as TGF-β/ALK5, during neuronal differentiation or in the context of viral latency, expands the experimental toolkit available to researchers. However, direct evidence for modulation of HSV-1 latency by TGF-β pathway inhibitors in this system is not yet established and should be regarded as a promising area for future investigation (workflow_recommendation).

Research Support Resources

Researchers aiming to reproduce or extend these workflows may require selective pathway modulators during hiPSC differentiation or mechanistic dissection. SB 431542 (SKU A8249) is a potent ALK5 inhibitor widely used to block TGF-β signaling, enhance neural lineage commitment, and facilitate pathway-specific studies in stem cell-derived systems (product_spec). For validated protocols and troubleshooting, consult internal resources or the supplier's technical documentation. Use of SB 431542 should be tailored to experimental context and is recommended for research use only.